SL Science Holding Ltd (SLBT)

Price$2.88Cached quoteAs of 2026-09-05 13:12 UTC

AI: Overvalued

Price checkThe market value is far too high for a tiny, loss-making preclinical business.

Multiplying approximately 560.76 million ordinary shares by the observed quote gives a market value near $1.13 billion. That equals roughly 515 times 2025 revenue, while the company lost $3.82 million and generated no approved-drug sales. Even adding June’s $7.8 million private financing to year-end cash leaves net cash immaterial beside that valuation. The price therefore appears to assume substantial clinical and commercial success before human trials have established safety or effectiveness.

Big pictureSales are unstable, losses are widening, and the business is consuming more cash.

Revenue rose from $0.88 million in 2023 to $3.36 million in 2024, then fell 35% to $2.20 million in 2025. Gross profit dropped 60% as the exosome business moved from direct sales toward lower-margin wholesale distribution. Operating loss widened from $1.20 million to $3.84 million. Free cash flow—cash left after running and investing in the business—was approximately negative $3.21 million, versus about negative $0.35 million in 2024. This record shows volatility, not a dependable sales cycle.

Business strengthLow debt helps, but the cash cushion is small beside planned clinical spending.

At year-end, cash was $1.26 million against $0.21 million of debt; current assets of $1.43 million exceeded current liabilities of $0.47 million. June’s $7.8 million gross private financing improved liquidity, but 2025’s cash burn suggests less than three years of theoretical funding before transaction costs or rising trial expenses. Capital went toward $2.07 million of research rather than dividends or buybacks. The merger issued 556.8 million shares to prior owners, while preferred shares may add another 260,000 ordinary shares after conversion.

What could change the storyHuman trial evidence or a major partnership could help, but neither exists yet.

The strongest bull case would require credible human evidence, regulatory clearance to begin trials, or a well-funded partner validating the licensed cell-therapy platform. Recovery in exosome sales would also reduce dependence on fundraising. The bear case is observable now: no candidate has entered human trials, the regulator requested additional evidence for the glioblastoma designation, and further capital will probably be needed. At roughly 515 times trailing sales, the market still assumes breakthroughs far beyond the results reported so far.

AI: News

Merger and Nasdaq debutSL Science listed through a merger and raised fresh cash for its early research programs.

The business combination closed on June 12, 2026, and trading began June 15. Former SL Bio owners received 556.8 million ordinary shares, while concurrent private financing raised $7.8 million gross. The transaction opened access to public capital for preclinical cell-therapy work, but its announced $5.568 billion implied equity valuation greatly exceeded the operating business’s revenue and cash. Subsequent price weakness cannot be attributed to the merger alone because reliable reporting has not isolated a cause.

Losses deepen sharplyRevenue fell while losses widened, showing the commercial business cannot yet fund drug development.

Results released June 18 showed 2025 revenue down 35% to $2.20 million and gross profit down 60% to $0.78 million. The operating loss more than tripled to $3.84 million as administrative spending rose and research remained near $2.07 million. All reported revenue came from legacy exosome products; the drug programs produced none. This matters because clinical development must be financed from a shrinking cash base, the recent financing, partnerships, or future share issuance.

Orphan request needs more dataThe United States drug regulator withheld the requested status and asked for stronger laboratory evidence.

SL Bio requested orphan-drug designation for its glioblastoma cell therapy on March 30, 2026. The company’s Form 20-F says the Food and Drug Administration declined to grant it on May 22 and requested efficacy testing after tumors are established plus confirmation of the studied product’s identity. A July 10 announcement described the request as under review, while September’s update said additional data were being prepared. The program remains preclinical, so the designation and eventual trial authorization remain uncertain.

Exosome manufacturing file addedA licensor filed manufacturing documents that could support later applications but did not prove efficacy.

On August 27, JY BioMed, the platform owner and SL Science’s licensor, filed Drug Master File number 044612 covering exosomes derived from its immune cells. A Drug Master File stores confidential manufacturing and quality information that later regulatory applications may reference, potentially reducing duplicated preparation. However, the filing belongs to the licensor, is not product approval, and supplies no human safety or effectiveness evidence. Its business value therefore depends on future licensed programs reaching formal clinical development.

Loading local price history

Revenue

2023

2024

2025

Net income

2023

2024

2025

Free cash flow

2023

2024

2025

Total cash / debt

CashTotal debt

2023

2024

2025

Financial statements

	2025	2024	2023
Revenue	$2.2M	$3.4M	$878,971
Gross profit	$775,062	$1.9M	$738,008
Gross margin	35.27%	57.46%	83.96%
Research & development	$2.1M	$2.0M	$0
Operating expenses	$4.6M	$3.1M	$641,180
Operating income	−$3.8M	−$1.2M	$96,828
Operating margin	−174.65%	−35.56%	11.02%
EBITDA	−$3.7M	−$1.1M	$134,019
EBITDA margin	−170.39%	−34.16%	15.25%
Net income	−$3.8M	−$1.2M	$399,035
Net profit margin	−173.85%	−35.42%	45.40%
Basic EPSper basic share	—	-$0.00	$0.00
Diluted EPSper diluted share	—	-$0.00	$0.00

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders

Top 2 reported holders of SLBT
Holder	Shares held
Wang Ching-Dong	333.83M
Xu Qian	20K

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)0$0.00 disclosed value

No insider transactions transactions were reported in the stored SEC coverage.

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about SLBT yet. Start the conversation.

Write the first post

SL Science Holding Ltd (SLBT)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.